RENAL ANEMIA TREATMENT IN THE US- HOW PAYER POLICIES AND PHYSICIAN PREFERENCES DRIVE PRESCRIBING AND HOW WILL THE EMERGING ORAL HIF-PH INHIBITORS INFLUENCE PAYERS AND PHYSICIANS?

Author(s)

Khan J¹, O'Connor E², Moore R³, Lewis C³, Fletcher-Louis M²
¹Decision Resources Group, Burlington, MA, USA, ²Decision Resources Group, London, UK, ³Decision Resources Group, Nashville, TN, USA

Presentation Documents

PUK22--strong-u-khan-j-u-sup-1-sup-strong-oconnor-e-sup-2-sup-moore-r-sup-3-sup-lewis-c-sup-3-sup-fletcher-louis-m-sup-2-sup-br-sup-1-sup-decision-resources-group-burlington-ma-usa-sup-2-sup-decision-resources-group-london-uk-sup-3-sup-deci ...

Conference/Value in Health Info

2016-10, ISPOR Europe 2016, Vienna, Austria

Value in Health, Vol. 19, No. 7 (November 2016)

Code

PUK22

Topic

Health Policy & Regulatory

Topic Subcategory

Reimbursement & Access Policy

Disease

Urinary/Kidney Disorders

Explore Related HEOR by Topic

Health Policy

Presentation